J. W. Clark

1.9k total citations · 1 hit paper
26 papers, 1.5k citations indexed

About

J. W. Clark is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research. According to data from OpenAlex, J. W. Clark has authored 26 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Pulmonary and Respiratory Medicine, 12 papers in Oncology and 10 papers in Cancer Research. Recurrent topics in J. W. Clark's work include Colorectal Cancer Treatments and Studies (8 papers), Lung Cancer Treatments and Mutations (8 papers) and Cancer, Hypoxia, and Metabolism (5 papers). J. W. Clark is often cited by papers focused on Colorectal Cancer Treatments and Studies (8 papers), Lung Cancer Treatments and Mutations (8 papers) and Cancer, Hypoxia, and Metabolism (5 papers). J. W. Clark collaborates with scholars based in United States, United Kingdom and Myanmar. J. W. Clark's co-authors include Stan B. Kaye, Timothy A. Yap, Johann S. de Bono, David P. Dearnaley, Colin S. Cooper, Elizabeth Folkerd, Mitch Dowsett, Mary Barrett, Florence I. Raynaud and Alison Reid and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Oncology and Science Translational Medicine.

In The Last Decade

J. W. Clark

25 papers receiving 1.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Phase I Clinical Trial of a Selective Inhibitor of CYP17, Abiraterone Acetate, Confirms That Castration-Resistant Prostate Cancer Commonly Remains Hormone Driven

2008 666 citations Gerhardt Attard, Alison Reid et al. Journal of Clinical Oncology profile →

Peers

Countries citing papers authored by J. W. Clark

Since Specialization

Citations

This map shows the geographic impact of J. W. Clark's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J. W. Clark with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J. W. Clark more than expected).

Fields of papers citing papers by J. W. Clark

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by J. W. Clark. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J. W. Clark. The network helps show where J. W. Clark may publish in the future.

Co-authorship network of co-authors of J. W. Clark

This figure shows the co-authorship network connecting the top 25 collaborators of J. W. Clark. A scholar is included among the top collaborators of J. W. Clark based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with J. W. Clark. J. W. Clark is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	The landscape of microbial associations in human cancer 2025 ·Science Translational Medicine ·Abraham Gihawi, Henry M. Wood, J. W. Clark, Justin O’Grady, Rosalind A. Eeles, David C. Wedge, (unknown), Gkikas Magiorkinis, Andrew Schache, Liam Masterson, (unknown), Tim R. Fenton, Terence M. Jones, Adrienne M. Flanagan, (unknown), Alex Rubinsteyn, Rachel Hurst, Colin S. Cooper, Daniel Brewer	2
2	Building Data-Driven Pathways From Routinely Collected Hospital Data: A Case Study on Prostate Cancer 2015 ·JMIR Medical Informatics ·Joao H. Bettencourt‐Silva, J. W. Clark, Colin S. Cooper, Robert Mills, V. J. Rayward‐Smith, Beatriz de la Iglesia	21
3	Phase I/II study of neoadjuvant bevacizumab, erlotinib and 5-fluorouracil with concurrent external beam radiation therapy in locally advanced rectal cancer 2013 ·Annals of Oncology ·Lawrence S. Blaszkowsky, David P. Ryan, Jackie Szymonifka, Darrell R. Borger, Andrew X. Zhu, J. W. Clark, E.L. Kwak, Harvey J. Mamon, Jill N. Allen, (unknown), Paul C. Shellito, James C. Cusack, David L. Berger, Theodore S. Hong	21
4	Impact of crizotinib on survival in patients with advanced, ALK-positive NSCLC compared with historical controls. 2011 ·Journal of Clinical Oncology ·Alice T. Shaw, B.Y. Yeap, Benjamin Solomon, Gregory J. Riely, A. John Iafrate, Geoffrey I. Shapiro, Daniel B. Costa, Mohit Butaney, S-H.I. Ou, Robert G. Maki, (unknown), Marileila Varella‐Garcia, Ravi Salgia, Keith D. Wilner, Kimary Kulig, Paulina Selaru, Yuan Tang, E.L. Kwak, J. W. Clark, D. Ross Camidge	28
5	An evaluation of blood mRNA expression array signatures derived from unsupervised analyses in the identification of prostate cancers with poor outcome. 2011 ·Journal of Clinical Oncology ·David Olmos, J. W. Clark, Daniel Brewer, (unknown), G. Attard, (unknown), Shahneen Sandhu, Andrea Zivi, Diletta Bianchini, (unknown), (unknown), L Rhoda Molife, S. B. Kaye, Catherine Parker, Colin Cooper, (unknown), Johann S. de Bono	1
6	Identification of a small and lethal subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib by MET amplification. 2011 ·Journal of Clinical Oncology ·Jochen K. Lennerz, E.L. Kwak, (unknown), Stephen B. Fox, A. B. Ackerman, Kristin Bergethon, Gregory Y. Lauwers, James G. Christensen, Keith D. Wilner, Daniel A. Haber, Ravi Salgia, Y-J. Bang, J. W. Clark, Benjamin Solomon, A. John Iafrate	6
7	A single-arm trial of panitumumab in cetuximab refractory KRAS wild-type colorectal cancer. 2011 ·Journal of Clinical Oncology ·Raymond Wadlow, Aram F. Hezel, Brian M. Wolpin, (unknown), Lawrence S. Blaszkowsky, E.L. Kwak, (unknown), Andrew X. Zhu, D. P. Ryan, J. W. Clark	3
8	Progression-free survival (PFS) from a phase I study of crizotinib (PF-02341066) in patients with ALK-positive non-small cell lung cancer (NSCLC). 2011 ·Journal of Clinical Oncology ·D. Ross Camidge, Yung‐Jue Bang, E.L. Kwak, Alice T. Shaw, A. John Iafrate, Robert G. Maki, Benjamin Solomon, S-H.I. Ou, Ravi Salgia, Keith D. Wilner, Daniel B. Costa, Geoffrey I. Shapiro, P. LoRusso, (unknown), Yi Tang, Katherine Ruffner, J. W. Clark	102
9	Clinical activity of the oral ALK inhibitor PF-02341066 in ALK-positive patients with non-small cell lung cancer (NSCLC). 2010 ·Journal of Clinical Oncology ·(unknown), E.L. Kwak, Alice T. Shaw, D. Ross Camidge, A. John Iafrate, Robert G. Maki, Benjamin Solomon, S-H.I. Ou, Ravi Salgia, J. W. Clark	105
10	Pharmacokinetics (PK) of PF-02341066, a dual ALK/MET inhibitor after multiple oral doses to advanced cancer patients. 2010 ·Journal of Clinical Oncology ·Weiwei Tan, Keith D. Wilner, (unknown), (unknown), Robert G. Maki, D. Ross Camidge, Benjamin Solomon, (unknown), Ravi Salgia, J. W. Clark	40
11	Weekly docetaxel, cisplatin, and irinotecan (TPC): results of a multicenter phase II trial in patients with metastatic esophagogastric cancer 2009 ·Annals of Oncology ·Peter C. Enzinger, D. P. Ryan, J. W. Clark, Alona Muzikansky, Craig C. Earle, Matthew H. Kulke, Jeffrey A. Meyerhardt, Lawrence S. Blaszkowsky, Andrew X. Zhu, P. Fidias, Michele Vincitore, Robert J. Mayer, Charles S. Fuchs	16
12	Phase I Clinical Trial of a Selective Inhibitor of CYP17, Abiraterone Acetate, Confirms That Castration-Resistant Prostate Cancer Commonly Remains Hormone Driven breakdown → 2008 ·Journal of Clinical Oncology ·Gerhardt Attard, Alison Reid, Timothy A. Yap, Florence I. Raynaud, Mitch Dowsett, S. Settatree, Mary Barrett, Christopher Parker, Vanessa Martins, Elizabeth Folkerd, J. W. Clark, Colin S. Cooper, Stan B. Kaye, David P. Dearnaley, Gloria Lee, Johann S. de Bono	666
13	Phase II study of RAD001 in previously treated patients with metastatic pancreatic cancer 2008 ·Journal of Clinical Oncology ·Brian M. Wolpin, Aram F. Hezel, D. P. Ryan, Thomas A. Abrams, J. A. Meyerhardt, Lawrence S. Blaszkowsky, J. W. Clark, Benjamin Allen, Eileen Regan, Charles S. Fuchs	9
14	O47 The prognostic impact of bone invasion in squamous cell carcinoma of the oral cavity 2007 ·R. R. Pate, Kun Gao, J. W. Clark, Claire O’Brien	0
15	Phase I study of neoadjuvant bevacizumab, 5-fluorouracil, and radiation therapy followed by surgery for patients with primary rectal cancer 2004 ·Journal of Clinical Oncology ·Christopher G. Willett, (unknown), D. Sahani, Masanobu Mino, J. W. Clark, D. P. Ryan, Andrew X. Zhu, (unknown), Gregory Y. Lauwers, (unknown)	14
16	Current perspectives on locally advanced pancreatic cancer. 2000 ·PubMed ·Brian G. Czito, Christopher G. Willett, J. W. Clark, (unknown)	20
17	Platelet-derived growth factor indirectly stimulates angiogenesis in vitro. 1993 ·PubMed Central ·Noboru Sato, Julie Beitz, Jun Kato, Masahide Yamamoto, J. W. Clark, Peter A. Calabresi, (unknown), A. Raymond Frackelton	121
18	The in vivo immunomodulatory effects of recombinant interferon gamma plus recombinant tumor necrosis factor-alfa. 1991 ·Journal of Clinical Oncology ·Walter J. Urba, William C. Kopp, J. W. Clark, John W. Smith, Ronald G. Steis, Christian G. Huber, (unknown), DL Longo	7
19	Phase I Evaluation of Recombinant Tumor Necrosis Factor Given in Combination With Recombinant Interferon-Gamma 1991 ·Journal of Immunotherapy ·John W. Smith, W J Urba, J. W. Clark, (unknown), (unknown), Stephen P. Creekmore, Kevin C. Conlon, Howard S. Jaffe, Ronald G. Steis	19
20	Effect of ethanol tolerance on release of acetylcholine and norepinephrine by rat cerebral cortex slices 1977 ·Canadian Journal of Physiology and Pharmacology ·J. W. Clark, H. Kalant, F. J. Carmichael	38

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact